Table 1.
Patient and clinical-pathologic characteristics (N = 200)
| Characteristic | Result |
|---|---|
| Follow-up, mo | |
| Median* (range) | 19 [10-34] |
| Age, y | |
| Median (range) | 65 [48-88] |
| Characteristic | No. (%) |
| Race | |
| White | 174 (87) |
| Asian | 7 (3.5) |
| African American | 7 (3.5) |
| Indian American | 1 (0.5) |
| Hispanic | 11 (5.5) |
| Breast cup size | |
| A | 4 (2) |
| B | 30 (15) |
| C | 50 (25) |
| D+ | 69 (34.5) |
| Not measured | 47 (23.5) |
| Lesion location | |
| UIQ | 32 (16) |
| LIQ | 16 (8) |
| Central | 26 (13) |
| UOQ | 102 (51) |
| LOQ | 11 (5.5) |
| Missing | 13 (6.5) |
| Histology | |
| DCIS | 28 (14) |
| Invasive ductal | 157 (78.5) |
| Invasive lobular | 14 (7) |
| Mixed invasive | 1 (0.5) |
| Tumor size, mm | |
| Median, [range] | 10, [1-28] |
| <5 | 17 (8.5) |
| ≥5 to <10 | 72 (36) |
| ≥10 to ≤20 | 95 (47.5) |
| >20 | 14 (7) |
| Unknown | 2 (1) |
| AJCC T tumor status | |
| Tis | 28 (14) |
| T1 | 158 (79) |
| T2, ≤3 cm | 13 (6.5) |
| T2, >3 cm | 1 (0.5) |
| Margins | |
| Negative | 184 (92) |
| Close (<2 mm) | 16 (8) |
| Positive | 0 (0) |
| Estrogen receptor | |
| Positive | 196 (98) |
| Negative | 4 (2) |
| Progesterone receptor | |
| Positive | 179 (89.5) |
| Negative | 20 (10) |
| Unknown | 1 (0.5) |
| Her2neu | |
| Positive | 8 (4) |
| Negative | 158 (79) |
| Equivocal | 5 (2.5) |
| Not done | 29 (14.5) |
Abbreviations: AJCC = American Joint Committee on Cancer; DCIS = ductal carcinoma in situ; LIQ = lower inner quadrant; LOQ = lower outer quadrant; Tis = in situ carcinoma; UIQ = upper inner quadrant; UOQ = upper outer quadrant.
*
Median follow-up calculated from treatment to date of current analysis.